#Canada #Hamilton #AtomVie #Ariceum #SANTANA-225

AtomVie Global Radiopharma Achieves Milestone in Cancer Treatment Development

In a significant breakthrough for cancer treatment, AtomVie Global Radiopharma has successfully supplied the first dose of 225Ac-SSO110 for Ariceum Therapeutics' groundbreaking clinical trial, SANTANA-225. This trial aims to evaluate the potential of this innovative radiopharmaceutical in treating small cell lung cancer (SCLC) and Merkel cell carcinoma (MCC) in advanced stages.

The Importance of This Development

This event marks a crucial step in the field of oncology. The innovative treatment approach offered by 225Ac-SSO110 is designed as a targeted therapy that leverages the unique properties of Actinium-225, a radioisotope known for its capability to deliver radiation directly to cancer cells. The SANTANA-225 trial, currently in its phase 1/2 stages, represents a new hope for patients battling aggressive and hard-to-treat cancers, which currently have limited therapeutic options.

Bruno Paquin, CEO of AtomVie, expressed his pride in this milestone: "We are honored to partner with Ariceum in supplying the critical quantity of 225Ac-SSO110 for the SANTANA-225 clinical trial. Our mission is to transform the lives of patients through high-quality radiopharmaceuticals, which drives every aspect of our work. We are proud to bridge promising oncology therapies to patients in need."

Collaboration with Ariceum Therapeutics

Ariceum Therapeutics, a clinical-stage oncology company, is committed to redefining the future of care through targeted radiotherapies for aggressive cancers. Manuel Sturzbecher-Höhne, Chief Technology Officer at Ariceum, affirmed the significance of AtomVie’s contributions, noting, "The administration of the first dose to our initial patient is a landmark event for Ariceum. We take pride in our collaboration with AtomVie for the production of 225Ac-SSO110. Their recognized expertise in Good Manufacturing Practices (GMP) and unwavering commitment to quality allow us to advance 225Ac-SSO110 through clinical development towards our mission of delivering transformative therapies to patients facing these challenging cancers."

AtomVie’s Role in the Clinical Trial

AtomVie is renowned as a contract development and manufacturing organization (CDMO) that specializes in the GMP manufacturing and global distribution of clinical and commercial radiopharmaceutical products. It provides a comprehensive suite of scientific, technical, regulatory, quality, and logistical services, combined with specialized infrastructures for developing radiopharmaceutical products from clinical studies to commercialization. Currently, AtomVie partners with global clients conducting clinical studies in over 28 countries, actively contributing to advancements in cancer care worldwide.

Looking forward, AtomVie is also constructing a state-of-the-art 72,300-square-foot facility, anticipated to launch by the end of 2025. This investment underscores the company’s dedication to enhancing its manufacturing capabilities and addressing rising demand in the radiopharmaceutical sector.

Conclusion

The initial dose administration of 225Ac-SSO110 represents more than just a clinical milestone; it symbolizes hope for variants of cancer that have traditionally faced grim prognoses. With companies like AtomVie and Ariceum leading the charge, the future of cancer therapeutics looks promising, opening new pathways for treatment and improving patient outcomes in historically challenging medical landscapes.